• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ProMIS Neurosciences Inc. (Amendment)

    9/5/23 4:30:38 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    SC 13G/A 1 tm2325480d2_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    ProMIS Neurosciences Inc.

    (Name of Issuer)

     

    Common Stock, No Par Value Per Share

    (Title of Class of Securities)

     

    74346M117

    (CUSIP Number)

     

    August 23, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     1 

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Michael S. Gordon 

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  x  (b)  ¨

      

    3.  

    SEC USE ONLY

      

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    0 

      6.  

    SHARED VOTING POWER

     

    1,737,005 

      7.  

    SOLE DISPOSITIVE POWER

     

    0 

      8.  

    SHARED DISPOSITIVE POWER

     

    1,737,005 

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,737,005 

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨ 

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.09% 

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IN 

      

     2 

     

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Title 19 Investments LLC (1) 

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) x  (b) ¨

      

    3.  

    SEC USE ONLY

      

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    0 

      6.  

    SHARED VOTING POWER

     

    0 

      7.  

    SOLE DISPOSITIVE POWER

     

    0 

      8.  

    SHARED DISPOSITIVE POWER

     

    0 

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0 

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨ 

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0% 

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    OO 

      

     

     

    1 The original Schedule 13G stated that Title 19 Investments LLC may be deemed to beneficially own 257,812 Common Shares. Ownership of these Common Shares was held by Title 19 Investments LLC at the time of such filing but should have been attributable to Title 19 Promis and has since been corrected. This Amendment No. 1 to Schedule 13G has been revised accordingly.

     

     3 

     

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Title 19 Acies 

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) x  (b) ¨

      

    3.  

    SEC USE ONLY

      

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    0 

      6.  

    SHARED VOTING POWER

     

    48,333 

      7.  

    SOLE DISPOSITIVE POWER

     

    0 

      8.  

    SHARED DISPOSITIVE POWER

     

    48,333 

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    48,333 

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨ 

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.26% 

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    OO 

      

     4 

     

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Title 19 Promis 

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) x  (b) ¨

      

    3.  

    SEC USE ONLY

      

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    0 

      6.  

    SHARED VOTING POWER

     

    1,688,672 

      7.  

    SOLE DISPOSITIVE POWER

     

    0 

      8.  

    SHARED DISPOSITIVE POWER

     

    1,688,672 

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,688,672 

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8% 

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    OO 

      

     5 

     

     

     

    Schedule 13G

     

    Explanatory Note:

     

    This Amendment No. 1 to Schedule 13G is filed jointly on behalf of Michael S. Gordon, Title 19 Investments LLC, a Delaware limited liability company (“Title 19 Investments”), Title 19 Acies, a series of a Delaware limited liability company (“Title 19 Acies”), and Title 19 Promis, a series of a Delaware limited liability company (“Title 19 Promis,” and collectively with Mr. Gordon, Title 19 Investments and Title 19 Acies, the “Reporting Persons”), pursuant to Rule 13d-1(c). Prior to the effective date of the registration of the Issuer’s common shares, no par value per share (“Common Shares”), pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, in July of 2021, (i) Title 19 Acies acquired 2,900,000 Common Shares, representing 48,333 Common Shares following a 60:1 stock split (the “Stock Split”) of the Issuer that occurred in June 2022, and (ii) Title 19 Promis acquired (a) 12,375,000 Common Shares, representing 206,250 Common Shares following the Stock Split, (b) 3,093,750 warrants to purchase Common Shares, each initially exercisable to purchase one Common Share and, as a result of the Stock Split, now exercisable to purchase an aggregate of 51,562 Common Shares, and (c) 30,000,000 Series 1 Preferred Shares (“Series 1 Preferred Shares”) of the Issuer, each initially convertible into one Common Share in accordance with the terms of the Series 1 Preferred Shares and, as a result of the Stock Split, now convertible into an aggregate of 500,000 Common Shares. On October 11, 2022, Title 19 Promis acquired 106,391 Common Shares and 26,597 warrants, each exercisable to purchase one Common Share, in a private placement conducted by the Issuer. On August 23, 2023, Title 19 Promis acquired 797,872 common share units, each consisting of one Common Share and one warrant to purchase one Common Share (the “August 2023 Warrants”), in a private placement conducted by the Issuer, which August 2023 Warrants are not currently exercisable. The August 2023 Warrants have an exercise price of $1.75 per whole warrant, are exercisable beginning February 23, 2024 and expire February 23, 2029. Such acquisition, when added to all other acquisitions of securities of the same class during the 12 months immediately preceding the date of such acquisition, aggregates to greater than two percent (2%) of the class of such securities. However, such acquisition was not done with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect. Accordingly, the Reporting Persons are filing this Amendment No. 1 to Schedule 13G pursuant to Rule 13d-1(c). 

     

    Item 1.

     

    (a)Name of Issuer

     

    The name of the Issuer is ProMIS Neurosciences Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    The principal executive offices of the Issuer are located at Suite 200, 1920 Yonge Street, Toronto, Ontario.

     

    Item 2.

     

    (a)Name of Person Filing

     

    This statement is filed by the Reporting Persons.

     

    (b)Address of the Principal Office or, if none, residence

     

    The address of the Reporting Persons is c/o JDJFOS, 2 Oliver Street, Suite 905, Boston, MA 02109.

     

    (c)Citizenship

     

    Mr. Gordon is a citizen of the United States of America. Title 19 Investments is a Delaware limited liability company. Title 19 Acies and Title 19 Promis are series of a Delaware limited liability company.

     

    (d)Title of Class of Securities

     

    The Schedule 13G statement relates to Common Shares of the Issuer.

     

    (e)CUSIP Number

     

    The CUSIP number for the Common Stock is 74346M117.

     

     6 

     

     

     

    Item 3.

     

    If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o):
           
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); 
           
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 
           
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 
           
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); 
           
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 
           
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); 
           
      (k) o Group, in accordance with §240.13d-1(b)(1)(ii)(K).

      

    Not Applicable. See Explanatory Note above.

     

    Item 4.     Ownership

     

    A.Michael S. Gordon

     

    (i)Mr. Gordon may be deemed the beneficial owner of 1,737,005 Common Shares, consisting of (a) 206,250 Common Shares (the “August 2021 Common Shares”) owned by Title 19 Promis, 51,562 Common Shares underlying warrants (the “March 2022 Warrants”) owned by Title 19 Promis to purchase Common Shares, which are currently exercisable, 904,263 Common Shares (the “October 2022 and August 2023 Common Shares”) owned by Title 19 Promis, 500,000 Common Shares underlying 30,000,000 Series 1 Preferred Shares (the “March 2022 Series 1 Preferred Shares”) owned by Title 19 Promis, which are currently convertible, and 26,597 Common Shares underlying warrants (the “October 2022 Warrants”) owned by Title 19 Promis, which are currently exercisable, and (b) 48,333 Common Shares (the “Title 19 Acies Common Shares”) owned by Title 19 Acies. Mr. Gordon is the sole manager of each of Title 19 Acies and Title 19 Promis.

     

    (ii)Mr. Gordon may be deemed the beneficial owner of 9.09% of the Common Shares outstanding. The percentage of beneficial ownership is based upon 18,525,253 Common Shares outstanding as of August 24, 2023, plus the Common Shares underlying the March 2022 Series 1 Preferred Shares, the Common Shares underlying the March 2022 Warrants and the Common Shares underlying the October 2022 Warrants.

     

    (iii)Number of Common Shares to which such person has:

     

    i.Sole power to vote or to direct the vote: 0

     

    ii.Shared power to vote or to direct the vote: 1,737,005

     

     7 

     

    iii.Sole power to dispose or to direct the disposition of: 0

     

    iv.Shared power to dispose or to direct the disposition of: 1,737,005

      

    B.Title 19 Acies

     

    (i)Title 19 Acies may be deemed to be the beneficial owner of the Title 19 Acies Common Shares.

     

    (ii)Title 19 Acies may be deemed the beneficial owner of 0.26% of the Common Shares outstanding. The percentage of beneficial ownership is based upon 18,525,253 Common Shares outstanding as of August 24, 2023.

     

    (iii)Number of Common Shares to which such person has:

     

    i.Sole power to vote or to direct the vote: 0

     

    ii.Shared power to vote or to direct the vote: 48,333

     

    iii.Sole power to dispose or to direct the disposition of: 0

     

    iv.Shared power to dispose or to direct the disposition of: 48,333

     

    C.Title 19 Promis

     

    (i)Title 19 Promis may be deemed to be the beneficial owner of 1,688,672 Common Shares, consisting of the August 2021 Common Shares, the October 2022 and August 2023 Common Shares, the Common Shares underlying the March 2022 Series 1 Preferred Shares, the Common Shares underlying the March 2022 Warrants, and the Common Shares underlying the October 2022 Warrants.

     

    (ii)Title 19 Promis may be deemed the beneficial owner of 8.8% of the Common Shares outstanding. The percentage of beneficial ownership is based upon 18,525,253 Common Shares outstanding as of August 24, 2023, plus the Common Shares underlying the March 2022 Series 1 Preferred Shares, the Common Shares underlying the March 2022 Warrants, and the Common Shares underlying the October 2022 Warrants.

     

    (iii)Number of Common Shares to which such person has:

     

    i.Sole power to vote or to direct the vote: 0

     

    ii.Shared power to vote or to direct the vote: 1,688,672

     

    iii.Sole power to dispose or to direct the disposition of: 0

     

    iv.Shared power to dispose or to direct the disposition of: 1,688,672

     

     8 

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    See Exhibit A attached hereto.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     9 

     

     

     

    Signature.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 5, 2023

     

     

    /s/ Michael S. Gordon 

      Michael S. Gordon
       
      TITLE 19 INVESTMENTS LLC
      TITLE 19 ACIES
      TITLE 19 PROMIS

     

      By:  

    /s/ Michael S. Gordon 

      Name: Michael S. Gordon
      Title: Manager

     

     

     

     10 

    Get the next $PMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    SEC Filings

    See more
    • SEC Form 10-Q filed by ProMIS Neurosciences Inc.

      10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:39:20 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:37:22 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

      DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

      4/29/25 5:15:09 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/24/24 6:56:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/18/24 4:15:05 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProMIS Neurosciences Announces First Quarter 2025 Financial Results

      First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. "We made significant

      5/12/25 7:30:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

      Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year end

      3/31/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

      CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) International Conference taking place in Vienna, Austria from April 1 - 4, 2025. The oral presentations are available on demand starting on Tuesday, April 1, 2025 at 7:00am C.E.T (2:00am E.T).

      3/24/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Milbury Max A.

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:04:11 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Development Officer Kaplan Johanne

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:03:06 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 4:56:13 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProMIS Neurosciences Inc.

      SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 3:36:04 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/6/24 4:15:57 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    See more
    • ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

      5/14/24 4:01:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

      4/1/24 4:15:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences, Inc. Announces Leadership Transition

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

      1/3/24 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care